Multiple sclerosis outcomes after cancer immunotherapy.

CONCLUSIONS: Reported MS relapses after ICI are rare, but the adverse events described include rapid neurologic progression and death. Larger and prospective studies are warranted to assess disability and long-term outcomes and outweigh the risks of starting immunotherapy in patients with MS.
PMID: 30788836 [PubMed - as supplied by publisher]

Source: Clinical Colorectal Cancer - February 20, 2019 Category: Cancer & Oncology Authors: Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL Tags: Clin Transl Oncol Source Type: research